Cibus, Inc.
CBUSHealthcareNASDAQBiotechnology · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Sep 3
Headquartered within the healthcare sector, Cibus, Inc. focuses on Biotechnology services and products. Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. Valued at $120.8M, CBUS is a micro-cap name in its sector. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients.
Market Cap
$120.8M
Beta
1.62
P/E (TTM)
—
P/E (Fwd)
-2.49
EPS (TTM)
$-1.53
EPS (Fwd)
$-0.64
ROE
-223.2%
ROA
-10.2%
Cash
$20.4M
Total Debt
$286.3M
Free CF
-$52.5M
52W Change
23.8%
Annual Financials
Cash vs Debt
Where CBUS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CBUS finished 20.00% below its 150-day moving average ($1.95) and 16.58% below its 200-day moving average ($1.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CBUS overbought or oversold?
At the September 3, 2026 close, CBUS's RSI(14) was 18.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, CBUS has $20.4M in cash with $286.3M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$52.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -223.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $157K (2022) to $3.6M (2025), reflecting a 2218% increase over the period.
With a beta above 1.5, CBUS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CBUS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.